Cardlytics Announces Fourth Quarter and Full Year 2025 Financial Results
Key Terms
adjusted EBITDA financial
free cash flow financial
non-GAAP financial
"In 2025, we took several steps to reset our business and improve our financial health,” said Amit Gupta, CEO of Cardlytics. "Going forward, we remain well positioned to execute our mandate and deliver for our partners and advertisers, even as we navigate a decrease in MQUs following the conclusion of our Bank of America campaigns in January. We are moving forward with sharper focus and discipline to control our own destiny by prioritizing our initiatives that build on our core fundamental strengths."
"It has been reinvigorating to rejoin the Cardlytics team,” said David Evans, CFO of Cardlytics. "I continue to believe in the strength and uniqueness of our platform. Leading up to this quarter, the business made several necessary decisions to right size our balance sheet to position the business for self-sustainability going forward. As such, we're taking a very focused, disciplined approach to execution and cost management in 2026."
Fourth Quarter 2025 Financial Results
-
Total Revenue was
$56.1 million 24.2% compared to$74.0 million -
Billings, a non-GAAP metric, was
$94.1 million 19.0% compared to$116.3 million -
Adjusted Contribution, a non-GAAP metric, was
$31.7 million 22.1% compared to$40.7 million -
Net Loss was
$(8.3) million $(0.15) $(15.6) million $(0.31) -
Adjusted EBITDA, a non-GAAP metric, was
$8.5 million $2.1 million $6.4 million -
Adjusted Net Income, a non-GAAP metric, was
$1.6 million $0.03 $0.2 million $0.00 -
Net cash provided by operating activities was
$13.0 million $10.0 million $3.0 million -
Free Cash Flow, a non-GAAP metric, was
$10.5 million $11.9 million $(1.5) million
Fiscal Year 2025 Financial Results
-
Total Revenue was
$233.3 million 16.2% compared to$278.3 million -
Billings, a non-GAAP metric, was
$385.0 million 13.3% compared to$443.8 million -
Adjusted Contribution, a non-GAAP metric, was
$130.3 million 13.4% compared to$150.5 million -
Net Loss was
$(103.5) million $(1.95) $(189.3) million $(3.91) -
Adjusted EBITDA, a non-GAAP metric, was
$10.1 million $7.5 million $2.5 million -
Adjusted Net Loss, a non-GAAP metric, was
$(17.3) million $(0.33) $(18.9) million $(0.39) -
Net cash provided by/(used in) operating activities was
$9.3 million $18.1 million $(8.8) million -
Free Cash Flow, a non-GAAP metric, was
$(6.5) million $21.6 million $(28.1) million
Key Metrics
-
Cardlytics MQUs in the quarter were 227.0 million, an increase of
18.4% compared to 191.7 million in the fourth quarter of 2024. For full year 2025, Cardlytics MQUs were 224.2 million, an increase of17.7% compared to 190.5 million in 2024. -
Cardlytics ACPU in the quarter was
$0.12 35.0% compared to$0.18 $0.50 25.4% compared to$0.67
Definitions of MQUs and ACPU are included below under the caption “Non-GAAP Measures and Other Performance Metrics.”
CARDLYTICS, INC.
|
||||||||||
|
Three Months Ended December 31, |
|
|
|||||||
|
|
2025 |
|
|
|
2024 |
|
|
Change % |
|
Billings(1) |
$ |
94,136 |
|
|
$ |
116,279 |
|
|
(19.0 |
)% |
Consumer Incentives |
|
38,041 |
|
|
|
42,283 |
|
|
(10.0 |
)% |
Revenue |
|
56,095 |
|
|
|
73,996 |
|
|
(24.2 |
)% |
Partner Share and other third-party costs |
|
24,395 |
|
|
|
33,285 |
|
|
(26.7 |
)% |
Adjusted Contribution(1) |
|
31,700 |
|
|
|
40,711 |
|
|
(22.1 |
)% |
Delivery costs |
|
5,810 |
|
|
|
7,979 |
|
|
(27.2 |
)% |
Gross Profit |
$ |
25,890 |
|
|
$ |
32,732 |
|
|
(20.9 |
)% |
Net Loss |
$ |
(8,250 |
) |
|
$ |
(15,590 |
) |
|
(47.1 |
)% |
Adjusted EBITDA(1) |
$ |
8,534 |
|
|
$ |
6,398 |
|
|
33.4 |
% |
|
|
|
|
|
|
|||||
Adjusted Contribution |
|
|
|
|
|
|||||
% of Billings |
|
33.7 |
% |
|
|
35.0 |
% |
|
|
|
% of Revenue |
|
56.5 |
% |
|
|
55.0 |
% |
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|||||
% of Billings |
|
9.1 |
% |
|
|
5.5 |
% |
|
|
|
% of Revenue |
|
15.2 |
% |
|
|
8.6 |
% |
|
|
|
(1) |
Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA." |
|
Year Ended December 31, |
|
||||||||
|
|
2025 |
|
|
|
2024 |
|
|
Change % |
|
Billings(1) |
$ |
384,958 |
|
|
$ |
443,840 |
|
|
(13.3 |
)% |
Consumer Incentives |
|
151,685 |
|
|
|
165,542 |
|
|
(8.4 |
)% |
Revenue |
|
233,273 |
|
|
|
278,298 |
|
|
(16.2 |
)% |
Partner Share and other third-party costs |
|
102,949 |
|
|
|
127,761 |
|
|
(19.4 |
)% |
Adjusted Contribution(1) |
|
130,324 |
|
|
|
150,537 |
|
|
(13.4 |
)% |
Delivery costs |
|
25,711 |
|
|
|
29,643 |
|
|
(13.3 |
)% |
Gross Profit |
$ |
104,613 |
|
|
$ |
120,894 |
|
|
(13.5 |
)% |
Net Loss |
$ |
(103,488 |
) |
|
$ |
(189,304 |
) |
|
(45.3 |
)% |
Adjusted EBITDA(1) |
$ |
10,057 |
|
|
$ |
2,523 |
|
|
298.6 |
% |
|
|
|
|
|
|
|||||
Adjusted Contribution |
|
|
|
|
|
|||||
% of Billings |
|
33.9 |
% |
|
|
33.9 |
% |
|
|
|
% of Revenue |
|
55.9 |
% |
|
|
54.1 |
% |
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|||||
% of Billings |
|
2.6 |
% |
|
|
0.6 |
% |
|
|
|
% of Revenue |
|
4.3 |
% |
|
|
0.9 |
% |
|
|
|
(1) |
Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA." |
First Quarter 2026 Financial Expectations
Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates):
|
Q1 2026 Guidance |
|
YoY Change |
Billings(1) |
|
|
( |
Revenue |
|
|
( |
Adjusted Contribution(2) |
|
|
( |
Adjusted EBITDA(2) |
( |
|
( |
(1) |
A reconciliation of Billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings." |
(2) |
A reconciliation of Adjusted Contribution to GAAP Gross Profit and a reconciliation of Adjusted EBITDA to GAAP Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure. |
Earnings Teleconference Information
Cardlytics will discuss its fourth quarter and full year 2025 financial results during a teleconference today, March 4, 2026, at 5:00 PM ET / 2:00 PM PT. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics’ website.
About Cardlytics
Cardlytics (NASDAQ: CDLX) is a commerce media platform, powered by our publishers’ first-party purchase data, that makes commerce smarter and more rewarding for everyone. We offer a range of solutions to help advertisers and publishers grow and strengthen customer loyalty. With visibility into approximately half of all card-based transactions in the
Cautionary Language Concerning Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to our growth opportunity, our ability to deliver stronger execution and shareholder value, our intention to strengthen our competitive position, enhance our product and tech capabilities and expand our network of partners and advertisers and our financial guidance for the first quarter of 2026. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.
Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association (“Chase”), Wells Fargo Bank, National Association (“Wells Fargo”), American Express Travel Related Services Company, Inc. (“American Express”) and a limited number of other financial institution (“FI”) partners; risks related to our ability to maintain relationships with Chase and Wells Fargo; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; our ability to consummate the closing of the Bridg sale and receipts of the proceeds therefrom; and other risks detailed in the “Risk Factors” section of our Form 10-K filed with the Securities and Exchange Commission on March 4, 2026 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.
The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Non-GAAP Measures and Other Performance Metrics
To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in
A “non-GAAP financial measure” refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.
We have presented Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. Adjusted Contribution measures the degree by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs. Adjusted Contribution does not take into account all costs associated with generating Revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. Management views Adjusted Contribution as the most relevant metric to measure the financial performance as it reflects the dollars we keep after all of our partners are paid. Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense; acquisition, integration and divestiture costs; change in contingent consideration; foreign currency loss/(gain); impairment of goodwill and intangible assets; gain on debt extinguishment; loss on divestiture; and, in applicable periods, certain other income and expense items, such as restructuring and reduction of force; income tax benefit; and deferred implementation costs. Adjusted Net Income (Loss) represents our Net Loss before stock-based compensation expense; foreign currency loss/(gain); acquisition, integration and divestiture costs (benefits); amortization of acquired intangibles; change in contingent consideration; impairment of goodwill and intangible assets; gain on debt extinguishment; and loss on divestiture, and in applicable periods, certain other income and expense items, such as restructuring and reduction of force and income tax benefit. We define Adjusted Net Income (Loss) per share as Adjusted Net Income (Loss) divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash provided by/(used in) operating activities, plus acquisition of property and equipment and capitalized software development costs. We believe Free Cash Flow is useful to measure the funds generated in a given period that are available for distribution or to sustain the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.
We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.
We define MQUs as targetable customers that have made a transaction using their account with an FI Partner or other partners in a given month, excluding pilot supply during the ramp up period, and whose transaction data was shared with Cardlytics. We then calculate a monthly average of these MQUs for the periods presented. We believe that the number of MQUs is an indicator of the Cardlytics platform's ability to drive engagement and is reflective of the consumer base and insights that we offer to marketers. We define ACPU as the Cardlytics platform Adjusted Contribution generated in the applicable period, divided by Cardlytics average MQUs in the applicable period. We believe that Adjusted Contribution is the most relevant metric as it reflects the value Cardlytics keeps after subtracting out rewards, Partner Share and other third-party costs. We believe that ACPU measures the Cardlytics platform's efficiency in converting marketer budgets into the value generated by customer engagement.
CARDLYTICS, INC.
|
|||||||
|
December 31, |
||||||
|
|
2025 |
|
|
|
2024 |
|
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
48,719 |
|
|
$ |
65,594 |
|
Accounts receivable and contract assets, net |
|
82,669 |
|
|
|
103,252 |
|
Other receivables |
|
2,587 |
|
|
|
3,801 |
|
Prepaid expenses and other assets |
|
3,304 |
|
|
|
5,336 |
|
Total current assets |
|
137,279 |
|
|
|
177,983 |
|
Long-term assets: |
|
|
|
||||
Property and equipment, net |
|
2,025 |
|
|
|
2,596 |
|
Right-of-use assets under operating leases, net |
|
4,947 |
|
|
|
6,341 |
|
Intangible assets, net |
|
5,553 |
|
|
|
11,371 |
|
Goodwill |
|
110,305 |
|
|
|
159,429 |
|
Capitalized software development costs, net |
|
24,214 |
|
|
|
33,341 |
|
Other long-term assets, net |
|
1,318 |
|
|
|
1,650 |
|
Total assets |
$ |
285,641 |
|
|
$ |
392,711 |
|
Liabilities and stockholders' (deficit) equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
3,360 |
|
|
$ |
3,689 |
|
Accrued liabilities: |
|
|
|
||||
Accrued compensation |
|
6,105 |
|
|
|
5,494 |
|
Accrued expenses |
|
7,725 |
|
|
|
7,175 |
|
Partner Share liability |
|
24,860 |
|
|
|
32,479 |
|
Consumer Incentive liability |
|
32,144 |
|
|
|
45,513 |
|
Deferred revenue |
|
2,589 |
|
|
|
2,154 |
|
Short-term debt |
|
— |
|
|
|
45,863 |
|
Current operating lease liabilities |
|
1,607 |
|
|
|
2,025 |
|
Current contingent consideration |
|
— |
|
|
|
4,563 |
|
Total current liabilities |
|
78,390 |
|
|
|
148,955 |
|
Long-term liabilities: |
|
|
|
||||
Convertible senior notes, net |
|
168,850 |
|
|
|
167,729 |
|
Line of credit |
|
40,070 |
|
|
|
— |
|
Long-term deferred revenue |
|
52 |
|
|
|
— |
|
Long-term operating lease liabilities |
|
4,787 |
|
|
|
6,034 |
|
Total liabilities |
|
292,149 |
|
|
|
322,718 |
|
Stockholders’ (deficit) equity: |
|
|
|
||||
Common stock, |
|
10 |
|
|
|
10 |
|
Additional paid-in capital |
|
1,399,542 |
|
|
|
1,366,958 |
|
Accumulated other comprehensive income |
|
(1,996 |
) |
|
|
3,601 |
|
Accumulated deficit |
|
(1,404,064 |
) |
|
|
(1,300,576 |
) |
Total stockholders’ (deficit) equity |
|
(6,508 |
) |
|
|
69,993 |
|
Total liabilities and stockholders’ (deficit) equity |
$ |
285,641 |
|
|
$ |
392,711 |
|
CARDLYTICS, INC.
|
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Revenue |
$ |
56,095 |
|
|
$ |
73,997 |
|
|
$ |
233,273 |
|
|
$ |
278,298 |
|
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Partner Share and other third-party costs |
|
24,395 |
|
|
|
33,285 |
|
|
|
102,949 |
|
|
|
127,761 |
|
Delivery costs |
|
5,810 |
|
|
|
7,979 |
|
|
|
25,711 |
|
|
|
29,643 |
|
Sales and marketing expense |
|
7,524 |
|
|
|
11,343 |
|
|
|
39,478 |
|
|
|
52,649 |
|
Research and development expense |
|
7,965 |
|
|
|
9,895 |
|
|
|
39,765 |
|
|
|
49,607 |
|
General and administrative expense |
|
9,730 |
|
|
|
13,770 |
|
|
|
47,267 |
|
|
|
56,482 |
|
Acquisition, integration and divestiture costs |
|
561 |
|
|
|
— |
|
|
|
561 |
|
|
|
161 |
|
Change in contingent consideration |
|
— |
|
|
|
100 |
|
|
|
102 |
|
|
|
210 |
|
Impairment of goodwill and intangible assets |
|
— |
|
|
|
— |
|
|
|
58,843 |
|
|
|
131,595 |
|
Gain on divestiture |
|
— |
|
|
|
— |
|
|
|
(4,831 |
) |
|
|
— |
|
Depreciation and amortization expense |
|
6,205 |
|
|
|
5,940 |
|
|
|
25,244 |
|
|
|
25,689 |
|
Total costs and expenses |
|
62,190 |
|
|
|
82,312 |
|
|
|
335,089 |
|
|
|
473,797 |
|
Operating loss |
|
(6,095 |
) |
|
|
(8,315 |
) |
|
|
(101,816 |
) |
|
|
(195,499 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
(2,139 |
) |
|
|
(1,694 |
) |
|
|
(7,919 |
) |
|
|
(5,553 |
) |
Foreign currency (loss) gain |
|
(16 |
) |
|
|
(5,581 |
) |
|
|
6,247 |
|
|
|
(1,269 |
) |
Gain on debt extinguishment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
13,017 |
|
Total other (expense) income |
|
(2,155 |
) |
|
|
(7,275 |
) |
|
|
(1,672 |
) |
|
|
6,195 |
|
Loss before income taxes |
|
(8,250 |
) |
|
|
(15,590 |
) |
|
|
(103,488 |
) |
|
|
(189,304 |
) |
Net Loss |
|
(8,250 |
) |
|
|
(15,590 |
) |
|
|
(103,488 |
) |
|
|
(189,304 |
) |
Net Loss per share, basic and diluted |
$ |
(0.15 |
) |
|
$ |
(0.31 |
) |
|
$ |
(1.95 |
) |
|
$ |
(3.91 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
54,318 |
|
|
|
51,005 |
|
|
|
53,114 |
|
|
|
48,361 |
|
CARDLYTICS, INC.
|
|||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||
|
2025 |
|
2024 |
|
2025 |
|
2024 |
||||
Delivery costs |
$ |
232 |
|
$ |
641 |
|
$ |
1,673 |
|
$ |
2,680 |
Sales and marketing expense |
|
901 |
|
|
1,877 |
|
|
4,611 |
|
|
10,017 |
Research and development expense |
|
1,917 |
|
|
2,926 |
|
|
10,431 |
|
|
14,957 |
General and administrative expense |
|
2,462 |
|
|
3,229 |
|
|
11,414 |
|
|
12,713 |
Total stock-based compensation expense |
$ |
5,512 |
|
$ |
8,673 |
|
$ |
28,129 |
|
$ |
40,367 |
CARDLYTICS, INC.
|
|||||||
|
Year Ended December 31, |
||||||
|
|
2025 |
|
|
|
2024 |
|
Operating activities |
|
|
|
||||
Net Loss |
$ |
(103,488 |
) |
|
$ |
(189,304 |
) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
||||
Credit loss expense |
|
2,134 |
|
|
|
6,106 |
|
Depreciation and amortization |
|
25,244 |
|
|
|
25,689 |
|
Amortization of financing costs charged to interest expense |
|
1,522 |
|
|
|
1,633 |
|
Amortization of right-of-use asset |
|
2,165 |
|
|
|
2,187 |
|
Impairment of goodwill and intangible assets |
|
58,843 |
|
|
|
131,595 |
|
Gain on debt extinguishment |
|
— |
|
|
|
(13,017 |
) |
Gain on divestiture |
|
(4,831 |
) |
|
|
— |
|
Stock-based compensation expense |
|
28,129 |
|
|
|
40,367 |
|
Change in contingent consideration |
|
102 |
|
|
|
210 |
|
Other non-cash expense (income), net |
|
(6,243 |
) |
|
|
1,481 |
|
Change in operating assets and liabilities: |
|
|
|
||||
Accounts receivable and contracts assets, net |
|
20,643 |
|
|
|
12,497 |
|
Prepaid expenses and other assets |
|
1,803 |
|
|
|
1,360 |
|
Accounts payable |
|
179 |
|
|
|
499 |
|
Other accrued expenses |
|
(724 |
) |
|
|
(6,644 |
) |
Partner Share liability |
|
(8,208 |
) |
|
|
(16,350 |
) |
Customer Incentive liability |
|
(7,980 |
) |
|
|
(7,133 |
) |
Net cash provided by (used in) operating activities |
|
9,290 |
|
|
|
(8,824 |
) |
Investing activities |
|
|
|
||||
Acquisition of property and equipment |
|
(480 |
) |
|
|
(1,562 |
) |
Capitalized software development costs |
|
(15,302 |
) |
|
|
(17,736 |
) |
Proceeds from divestitures, net of cash divested |
|
480 |
|
|
|
552 |
|
Net cash used in investing activities |
|
(15,302 |
) |
|
|
(18,746 |
) |
Financing activities |
|
|
|
||||
Proceeds from issuance of debt |
|
56,000 |
|
|
|
172,500 |
|
Principal payments of debt |
|
(62,000 |
) |
|
|
(199,303 |
) |
Proceeds from termination of capped calls related to convertible notes |
|
— |
|
|
|
115 |
|
Proceeds from issuance of common stock |
|
— |
|
|
|
48,645 |
|
Settlement of contingent consideration |
|
(5,000 |
) |
|
|
(14,167 |
) |
Deferred equity issuance costs |
|
— |
|
|
|
(309 |
) |
Debt issuance costs |
|
(122 |
) |
|
|
(6,037 |
) |
Net cash (used in) provided by financing activities |
|
(11,122 |
) |
|
|
1,444 |
|
Effect of exchange rates on cash, cash equivalents and restricted cash |
|
259 |
|
|
|
(110 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
(16,875 |
) |
|
|
(26,236 |
) |
Cash, cash equivalents, and restricted cash — Beginning of period |
|
65,594 |
|
|
|
91,830 |
|
Cash, cash equivalents, and restricted cash — End of period |
$ |
48,719 |
|
|
$ |
65,594 |
|
CARDLYTICS, INC.
|
|||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||
|
2025 |
|
2024 |
|
2025 |
|
2024 |
||||
Revenue |
$ |
56,095 |
|
$ |
73,996 |
|
$ |
233,273 |
|
$ |
278,298 |
Plus: |
|
|
|
|
|
|
|
||||
Consumer Incentives |
|
38,041 |
|
|
42,283 |
|
|
151,685 |
|
|
165,542 |
Billings |
$ |
94,136 |
|
$ |
116,279 |
|
$ |
384,958 |
|
$ |
443,840 |
CARDLYTICS, INC.
|
|||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||
|
2025 |
|
2024 |
|
2025 |
|
2024 |
||||
Revenue |
$ |
56,095 |
|
$ |
73,996 |
|
$ |
233,273 |
|
$ |
278,298 |
Minus: |
|
|
|
|
|
|
|
||||
Partner Share and other third-party costs |
|
24,395 |
|
|
33,285 |
|
|
102,949 |
|
|
127,761 |
Delivery costs(1) |
|
5,810 |
|
|
7,979 |
|
|
25,711 |
|
|
29,643 |
Gross Profit |
|
25,890 |
|
|
32,732 |
|
|
104,613 |
|
|
120,894 |
Plus: |
|
|
|
|
|
|
|
||||
Delivery costs(1) |
|
5,810 |
|
|
7,979 |
|
|
25,711 |
|
|
29,643 |
Adjusted Contribution |
$ |
31,700 |
|
$ |
40,711 |
|
$ |
130,324 |
|
$ |
150,537 |
(1) |
Stock-based compensation expense recognized in delivery costs totaled |
CARDLYTICS, INC.
|
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Net Loss |
$ |
(8,250 |
) |
|
$ |
(15,590 |
) |
|
$ |
(103,488 |
) |
|
$ |
(189,304 |
) |
Plus: |
|
|
|
|
|
|
|
||||||||
Interest expense, net |
|
2,139 |
|
|
|
1,694 |
|
|
|
7,919 |
|
|
|
5,553 |
|
Depreciation and amortization |
|
6,205 |
|
|
|
5,940 |
|
|
|
25,244 |
|
|
|
25,689 |
|
Stock-based compensation expense |
|
5,512 |
|
|
|
8,673 |
|
|
|
28,129 |
|
|
|
40,367 |
|
Acquisition, integration and divestiture costs |
|
561 |
|
|
|
— |
|
|
|
561 |
|
|
|
161 |
|
Change in contingent consideration |
|
— |
|
|
|
100 |
|
|
|
102 |
|
|
|
210 |
|
Foreign currency loss (gain) |
|
16 |
|
|
|
5,581 |
|
|
|
(6,247 |
) |
|
|
1,269 |
|
Impairment of goodwill and intangible assets |
|
— |
|
|
|
— |
|
|
|
58,843 |
|
|
|
131,595 |
|
Gain on debt extinguishment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,017 |
) |
Gain on divestiture |
|
— |
|
|
|
— |
|
|
|
(4,831 |
) |
|
|
— |
|
Restructuring and reduction of force |
|
2,351 |
|
|
|
— |
|
|
|
3,825 |
|
|
|
— |
|
Adjusted EBITDA |
$ |
8,534 |
|
|
$ |
6,398 |
|
|
$ |
10,057 |
|
|
$ |
2,523 |
|
CARDLYTICS, INC.
|
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Net Loss |
$ |
(8,250 |
) |
|
$ |
(15,590 |
) |
|
$ |
(103,488 |
) |
|
$ |
(189,304 |
) |
Plus: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation expense |
|
5,512 |
|
|
|
8,673 |
|
|
|
28,129 |
|
|
|
40,367 |
|
Foreign currency loss (gain) |
|
16 |
|
|
|
5,581 |
|
|
|
(6,247 |
) |
|
|
1,269 |
|
Acquisition, integration and divestiture costs (benefits) |
|
561 |
|
|
|
— |
|
|
|
561 |
|
|
|
161 |
|
Amortization of acquired intangibles |
|
1,455 |
|
|
|
1,455 |
|
|
|
5,818 |
|
|
|
9,810 |
|
Change in contingent consideration |
|
— |
|
|
|
100 |
|
|
|
102 |
|
|
|
210 |
|
Impairment of goodwill and intangible assets |
|
— |
|
|
|
— |
|
|
|
58,843 |
|
|
|
131,595 |
|
Gain on debt extinguishment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,017 |
) |
Gain on divestiture |
|
— |
|
|
|
— |
|
|
|
(4,831 |
) |
|
|
— |
|
Restructuring and reduction of force |
|
2,351 |
|
|
|
— |
|
|
|
3,825 |
|
|
|
— |
|
Adjusted Net Income (Loss) |
$ |
1,645 |
|
|
$ |
219 |
|
|
$ |
(17,288 |
) |
|
$ |
(18,909 |
) |
Weighted-average number of shares of common stock used in computing Adjusted Net Income (Loss) per share: |
|
|
|
|
|
|
|
||||||||
GAAP weighted-average common shares outstanding, diluted |
|
54,318 |
|
|
|
51,005 |
|
|
|
53,114 |
|
|
|
48,361 |
|
Adjusted Net Income (Loss) per share, diluted |
$ |
0.03 |
|
|
$ |
0.00 |
|
|
$ |
(0.33 |
) |
|
$ |
(0.39 |
) |
CARDLYTICS, INC.
|
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Net cash provided by (used in) operating activities |
$ |
13,010 |
|
|
$ |
2,979 |
|
|
$ |
9,290 |
|
|
$ |
(8,824 |
) |
Plus: |
|
|
|
|
|
|
|
||||||||
Acquisition of property and equipment |
|
(25 |
) |
|
|
(123 |
) |
|
|
(480 |
) |
|
|
(1,562 |
) |
Capitalized software development costs |
|
(2,532 |
) |
|
|
(4,313 |
) |
|
|
(15,302 |
) |
|
|
(17,736 |
) |
Free Cash Flow |
$ |
10,453 |
|
|
$ |
(1,457 |
) |
|
$ |
(6,492 |
) |
|
$ |
(28,122 |
) |
CARDLYTICS, INC.
|
|
|
Q1 2026 Guidance |
Revenue |
|
Plus: |
|
Consumer Incentives |
|
Billings |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304946746/en/
Public Relations:
pr@cardlytics.com
Investor Relations:
ir@cardlytics.com
Source: Cardlytics, Inc.
